Perhaps it's not all too surprising to witness the S&P 500 run into turbulence after two of the best years for stock gains in recent memory.
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences, Inc. (NASDAQ:GILD ) BofA Securities Health Care Conference May 13, 2025 2:20 PM ET Company Participants Johanna Mercier – Chief Commercial Officer Conference Call Participants Tim A
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t
When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with ch
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the Euro
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE